• Explore /
  • Poster
  • / Capmatinib in patients with <em>METex14</em>-mutated or high-level <em>MET</em>-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.

Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.

Abstract Video & Slides Poster

Authors

Harry Groen

Harry J.M. Groen

University of Groningen and University Medical Center Groningen, Groningen, Netherlands

Harry J.M. Groen , Wallace L. Akerley , Pierre Jean Souquet , Eckart Laack , Ji-Youn Han , Egbert F. Smit , Aaron Scott Mansfield , Edward B. Garon , Juergen Wolf , Daniel Shao-Weng Tan , Rebecca Suk Heist , Maeve Waldron-Lynch , Sylvie Le Mouhaer , Ngozi Nwana , Monica Giovannini , Sergey Orlov

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02414139

Citation

J Clin Oncol 38: 2020 (suppl; abstr 9520)

DOI

10.1200/JCO.2020.38.15_suppl.9520

Abstract #

9520

Poster Bd #

286

Abstract Disclosures

Similar Posters

First Author: Yuangyuan Zhao

First Author: Tony S. K. Mok

First Author: Atsushi Nakamura

First Author: Rebecca Suk Heist